Abeona Therapeutics Company Profile (OTCMKTS:ACCP)

About Abeona Therapeutics (OTCMKTS:ACCP)

Abeona Therapeutics logoAbeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company's lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene editing approach to gene therapy program for rare blood diseases. It is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease. Its product pipeline also consists of MuGard and ProdiGard.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:ACCP
  • CUSIP: N/A
  • Web: N/A
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Dividend:
  • Dividend Yield: 1.0%
 

Frequently Asked Questions for Abeona Therapeutics (OTCMKTS:ACCP)

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the OTCMKTS under the ticker symbol "ACCP."

Who are some of Abeona Therapeutics' key competitors?

Who are Abeona Therapeutics' key executives?

Abeona Therapeutics' management team includes the folowing people:

  • Steven H Rouhandeh, Executive Chairman of the Board
  • Timothy J Miller Ph.D., President, Chief Executive Officer, Director
  • Harrison G Wehner III, Chief Financial Officer
  • Jeffrey B. Davis, Chief Operating Officer, Director
  • Stephen B. Thompson, Chief Accounting Officer, Vice President - Finance, Treasurer, Secretary
  • Todd Wider M.D., Director
  • Mark J. Alvino, Independent Director
  • Stephen B. Howell M.D., Independent Director

How do I buy Abeona Therapeutics stock?

Shares of Abeona Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Abeona Therapeutics stock cost?

One share of Abeona Therapeutics stock can currently be purchased for approximately $0.22.

Analyst Ratings

Consensus Ratings for Abeona Therapeutics (OTCMKTS:ACCP) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Abeona Therapeutics (OTCMKTS:ACCP)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Abeona Therapeutics (OTCMKTS:ACCP)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Abeona Therapeutics (OTCMKTS:ACCP)
Current Year EPS Consensus Estimate: $0.70 EPS

Dividends

Dividend History for Abeona Therapeutics (OTCMKTS:ACCP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Abeona Therapeutics (OTCMKTS:ACCP)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Abeona Therapeutics (OTCMKTS:ACCP)
Latest Headlines for Abeona Therapeutics (OTCMKTS:ACCP)
Source:
DateHeadline
seekingalpha.com logoAbeona's gene therapy EB-101 an Orphan Drug for rare inherited skin-blistering disorder
seekingalpha.com - May 25 at 3:34 PM
seekingalpha.com logoAbeona's gene therapy EB-101 an Orphan Drug for rare inherited skin-blistering disorder
seekingalpha.com - May 25 at 3:34 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Announces FDA Orphan Drug Designation for EB-101 Gene Therapy for Patients with DEB
www.streetinsider.com - May 25 at 3:34 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Announces FDA Orphan Drug Designation for EB-101 Gene Therapy for Patients with DEB
www.streetinsider.com - May 25 at 3:34 PM
seekingalpha.com logoAbeona Therapeutics Q1 revenues $186K, cash consumption $5.9M
seekingalpha.com - May 16 at 3:19 PM
reuters.com logoBRIEF-Abeona Therapeutics Q1 loss per share $0.13
www.reuters.com - May 16 at 3:19 PM
reuters.com logoBRIEF-Abeona says ABO-102 well-tolerated in six subjects through 1100 days follow up
www.reuters.com - May 13 at 1:41 AM
nasdaq.com logoAbeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa
www.nasdaq.com - May 3 at 3:18 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Announces EU Orphan Drug Designation for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
www.streetinsider.com - March 8 at 3:18 PM
reuters.com logoBRIEF-Abeona Therapeutics announces dismissal of securities class action lawsuit
www.reuters.com - February 23 at 3:18 PM
finance.yahoo.com logoAbeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit
finance.yahoo.com - February 23 at 3:18 PM
reuters.com logoBRIEF-Abeona Therapeutics provides update from phase 1/2 MPS IIIA clinical trial
www.reuters.com - February 17 at 6:48 PM
finance.yahoo.com logoABEO UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving …
finance.yahoo.com - February 10 at 3:19 PM
finance.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Abeona …
finance.yahoo.com - February 8 at 8:22 PM
benzinga.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP...
www.benzinga.com - January 25 at 1:44 AM
seekingalpha.com logoPremarket analyst action - new coverage
seekingalpha.com - January 6 at 8:26 PM
streetinsider.com logoAbeona Therapeutics (ABEO) ABO-201 Program Granted Orphan Drug Designation in Europe
www.streetinsider.com - January 3 at 3:25 PM
zacks.com logoAbeona Therapeutics (ABEO): Strong Industry, Solid Earnings Estimate Revisions
www.zacks.com - January 3 at 8:14 AM
reuters.com logoBRIEF-Abeona Therapeutics receives orphan drug designation in the EU for ABO-201 gene therapy program
www.reuters.com - January 3 at 8:14 AM
businesswire.com logoINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Abeona Therapeutics Inc. To Contact Brower Piven Before The Lead ...
www.businesswire.com - December 30 at 1:23 AM
seekingalpha.com logoAbeona - Considerable Upside Potential With Near Term Catalysts
seekingalpha.com - December 22 at 8:18 PM
benzinga.com logoGainey McKenna & Egleston Announces A Class...
www.benzinga.com - December 17 at 1:27 AM
finance.yahoo.com logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Abeona Therapeutics …
finance.yahoo.com - December 17 at 1:27 AM
seekingalpha.com logoAbeona slips 8% on bearish call from Mako Research
seekingalpha.com - December 12 at 3:23 PM
seekingalpha.com logoAbeona Therapeutics beats by $0.11, misses on revenue
seekingalpha.com - November 10 at 1:40 PM
seekingalpha.com logoAbeona prices 6M-share stock offering; shares ease 2%
seekingalpha.com - October 27 at 3:31 PM
finance.yahoo.com logoAbeona Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - October 27 at 3:31 PM
thestreet.com logoInteresting ABEO Put And Call Options For June 2017
www.thestreet.com - October 24 at 3:18 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Updates on ABO-102 Phase 1/2 MPS IIIA; Significant Avg. GAG Reduction Noted
www.streetinsider.com - October 20 at 3:16 PM

Social

Chart

Abeona Therapeutics (ACCP) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff